Rohto Q1 shows strong Asia growth driven by EYS acquisition

Rohto Pharmaceutical's Q1 results reveal robust growth, largely propelled by its Asia segment, specifically the consolidation of Eu Yan Sang International (EYS), which contributed an estimated ¥9.0 billion to sales and drove significant increases in Southeast Asia. While Japan saw gains in eye care and specific product lines, its overall skincare segment growth was modest at 0.7%, with key brands like Hada Labo slowing and Melano CC declining. Analysts note potential challenges for recent price increases amid intense competition, highlighting Rohto's increasing reliance on international expansion, particularly in Asia, as its primary growth driver, while facing headwinds in its domestic market.

Analysis

Rohto Pharmaceutical's Q1 results illustrate a heavy reliance on its international M&A strategy to drive growth, which is currently masking significant weakness in its core domestic market. The Asia segment's ¥11.6 billion sales increase was overwhelmingly powered by the consolidation of Eu Yan Sang International (EYS), which contributed an estimated ¥9.0 billion, highlighting the acquisition's immediate top-line impact. This inorganic growth is further supported by strong organic performance in Southeast Asia, with sales in Indonesia and Vietnam growing in the mid-30s and low teens percentages, respectively. In stark contrast, the Japanese market is stagnating, contributing only ¥0.24 billion to the quarterly sales increase. The critical Japan Skincare segment grew a mere 0.7%, dragged down by a sharp deceleration in the major Hada Labo brand to 1% growth from 5.5% in the prior quarter and a 10% decline in Melano CC. While August price increases on 27 items could offer a lift, analysts caution that their effectiveness may be limited due to intense competition from low-priced alternatives, posing a risk to both volume and margin.

Key Decisions for Investors

• Investors should view Rohto primarily as an Asian M&A integration play, focusing on the sustained performance of Eu Yan Sang and continued momentum in Southeast Asian markets as the key drivers for future valuation.
• It is critical to monitor the performance of the domestic Japan skincare segment, as the sharp slowdown in key brands like Hada Labo represents a material headwind to organic growth and could signal deeper competitive issues.
• Scrutinize the impact of recent price hikes on sales volume and market share in the coming quarters, as their potential failure to stick amidst fierce competition could undermine future profitability forecasts.